IMA is loading

Main Financial Data 2010

Main Data: 31/12 Year 2010
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 503.27
– gross industrial income 202.24
– total operating cost 159.04
– operating profit 43.20
– net financial expenses 7.13
– group profit 17.00

 

Consolidated balance sheet Millions/Euro
– working capital 74.07
– non-current assets 166.91
– provision for severance indemnities and other provisions – 11.59
– net debt – 113.51
– equity pertaining to the group and minority interests 115.88

 

Other information Millions/Euro
– depreciation, amortization and impairment 16.10
– R & D costs 26.42

 

  Euro
Dividend per share 0.90

 

  No.
Employees 3,129

 

  Euro
Share capital 17,732,000

 

Main Data: 30/06 Year 2010
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 196.1
– gross industrial income 79.3
– total operating cost 77.6
– operating profit 1.7
– net financial expenses 3.0
– group profit (loss) – 1.3

 

Consolidated balance sheet Millions/Euro
– working capital 104.0
– non-current assets 160.5
– provision for severance indemnities and other provisions – 16.1
– net debt – 150.2
– equity pertaining to the group and minority interests 98.2

 

Other information Millions/Euro
– depreciation, amortization and impairment 6.4
– R & D costs 13.7

 

  No.
Employees 3,071

 

  Euro
Share capital 17,732,000

 

Net Sales by Sector: Year 2010
  Millions/Euro  
tea, herbs & coffee 87.61 17.4%
pharmaceuticals packaging 283.45 56.3%
pharmaceuticals processing 113.01 22.5%
other 19.20 3.8%
Total 503.27 100.0%

 

Net Sales by Country: Year 2010
  Millions/Euro  
E.U. (excluding Italy) 180.09 35.8%
Other European countries 37.01 7.3%
North America 72.77 14.5%
Asia & Middle East 131.00 26.0%
Other countries 40.34 8.0%
Total exports 461.21 91.6%
Italy 42.06 8.4%
Total 503.27 100.0%

 

Dismissclose

IMA Pharma
@ Achema

Explore the dedicated website and get a free entry pass with IMA